Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
Hong Kong Med J. 2011 Dec;17(6):446-52.
To determine the period prevalence, demographic characteristics, cost of treatment, and outcomes of patients admitted to the intensive care unit for continuous renal replacement therapy.
Descriptive case series.
Intensive Care Unit in a Hong Kong tertiary referral, teaching hospital.
All patients admitted to the Intensive Care Unit from January to December 2007 who underwent continuous renal replacement therapy.
Period prevalence of continuous renal replacement therapy, patient demographic data, referral sources by specialty and hospital location, diagnosis, daily cost of disposable items, duration of renal replacement therapy, intensive care unit length of stay, and hospital mortality.
Of 1652 patients admitted to the intensive care unit over a 12-month period, 131 (8%) underwent continuous renal replacement therapy, of whom 56% were admitted from general wards (the department of medicine being the source of 59% of referrals). The median age of these continuous renal replacement therapy patients was 67 (interquartile range, 55-76) years, with a slight male predominance (66%). The mean APACHE II score of the patients was 29 (standard deviation, 7). Chronic renal failure requiring either haemodialysis or peritoneal dialysis was present in 20/131 (15%) patients. Sepsis was the diagnosis most commonly associated with renal failure deemed to warrant continuous renal replacement therapy (43%). The median duration of such continuous therapy was 55 (interquartile range, 25-93) hours and the median intensive care unit length of stay was 120 (interquartile range, 51-289) hours. The mean daily cost of disposables for the provision of continuous renal replacement therapy was HK$3510. The overall intensive care unit mortality of patients having continuous renal replacement therapy was 38% and the hospital mortality was 53%. The corresponding rates for patients with acute renal failure were 45% and 56%, respectively. Patients undergoing continuous renal replacement therapy had prolonged intensive care unit stays (120 vs 24 hours; P<0.05) and higher corresponding hospital mortality rates (53% vs 20%; P<0.001) compared to those not having such therapy.
The 8% period prevalence of patients admitted to the intensive care unit undergoing continuous renal replacement therapy was somewhat higher than in recently published reports in the international literature. However intensive care unit and hospital mortality rates for such patients were lower than previously reported. The corresponding total daily cost of relevant disposables was similar to costs reported internationally, whilst the length of intensive care unit stays for our cohort were relatively short.
确定因持续肾脏替代治疗而入住重症监护病房的患者的时期患病率、人口统计学特征、治疗费用和转归。
描述性病例系列。
香港一家三级转诊、教学医院的重症监护病房。
2007 年 1 月至 12 月期间入住重症监护病房并接受持续肾脏替代治疗的所有患者。
持续肾脏替代治疗的时期患病率、患者人口统计学数据、按专科和医院地点的转诊来源、诊断、一次性用品的日费用、肾脏替代治疗持续时间、重症监护病房住院时间和院内死亡率。
在 12 个月期间,1652 名入住重症监护病房的患者中,有 131 名(8%)接受了持续肾脏替代治疗,其中 56%是从普通病房转入(内科是 59%转诊来源)。这些接受持续肾脏替代治疗的患者的中位年龄为 67 岁(四分位间距,5576 岁),男性略占优势(66%)。患者的平均急性生理和慢性健康状况评分Ⅱ(APACHE Ⅱ)为 29 分(标准差,7 分)。20/131 名(15%)患者患有慢性肾衰竭,需要血液透析或腹膜透析。败血症是与需要持续肾脏替代治疗的肾衰竭相关的最常见诊断(43%)。这种持续治疗的中位时间为 55 小时(四分位间距,2593 小时),中位重症监护病房住院时间为 120 小时(四分位间距,51~289 小时)。提供持续肾脏替代治疗的一次性用品的日平均费用为 3510 港元。接受持续肾脏替代治疗的患者重症监护病房总死亡率为 38%,医院死亡率为 53%。急性肾衰竭患者的相应死亡率分别为 45%和 56%。与未接受此类治疗的患者相比,接受持续肾脏替代治疗的患者重症监护病房住院时间延长(120 小时 vs 24 小时;P<0.05),相应的医院死亡率更高(53% vs 20%;P<0.001)。
入住重症监护病房接受持续肾脏替代治疗的患者的 8%时期患病率高于国际文献中最近发表的报告,但此类患者的重症监护病房和医院死亡率低于先前报告。相应的一次性用品总成本与国际报告相似,而本队列的重症监护病房住院时间相对较短。